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In this issue Hoffmann and colleagues [1] present
further information about the views of medical
decision makers in the UK National Health Service
(NHS) on the usefulness of published economic
evaluations. As the authors state, the study largely
conﬁrms the results of previous studies by them-
selves and others. The Hoffmann study used a focus
group approach with a convenience sample of 
decision makers from two cooperative English
health authorities and selected studies from a data-
base controlled by the authors’ institutions. Given
its design, the study probably says more about the
usefulness of the NHS Economic Evaluation Data-
base (EED) than about the more general issues
regarding the use of economics in health-care 
decisions.
However, a strength of the study is that it directly
records the views of the groups of decision makers
about how the information in the NHS EED could
be made more useful to them. Hoffmann and 
colleagues are careful to emphasize the respective
roles of the researchers and subjects in the study and
quite naturally have been restrained in their com-
ments on the validity of the views expressed. To us
the study raises some fundamental questions that
are not explicitly addressed in the paper, even in the
request for further research.
The general assumption has been that if 
economic evaluations are being carried out to aid
health-care decision making and decision makers do
not ﬁnd them useful, then the way the evaluations
are conducted or presented must be changed. The
economic approach to evaluation is based on the
synthesis of information to identify the most efﬁ-
cient way to achieve predetermined objectives. In
the health-care ﬁeld, the principal pieces of infor-
mation are health outcomes and the resources used
to achieve them. The objectives are generally to
maximize the health gain within the constraints of
available resources and equity concerns. The con-
straints can be changed and the method of measur-
ing the outcomes can be varied, but the basic
approach remains the same.
If this economic decision framework is not satis-
factory for NHS decision makers, then it must be
assumed that they have a different and superior
model of decision making.
Exactly how decisions are made on service plan-
ning and resource allocation in the NHS without
substantive economic input is a question that seems
eminently suitable for further research. If this as 
yet undeﬁned approach to decision making can be
compared with the economic model and shown to
be superior, then perhaps the current efforts to carry
out economic evaluations (and adapt the results to
meet the perceived needs of decision makers) can 
be reduced. We would also be spared the need to
try continually to improve the level of understand-
ing of economic evaluation among medical decision
makers evidenced by Hoffmann and colleagues.
In the absence of a clear understanding of 
how decisions are actually being made by health
authorities, economists might be more questioning
of the validity of criticisms of their work.
The participants in the focus groups in the 
Hoffmann study suggested several changes to the
format of the entries in the NHS EED to make it
easier for them to use. For example, they wanted
the commentaries to be more critical and to appear
at the start of the abstract. They would prefer
studies to be scored for quality. Put another way,
this could be interpreted as a desire of the partici-
pants to read only a commentary rather than a
whole abstract, and preferably to have someone else
tell them how good the study is to save them the
trouble of reading it at all.
There were concerns over the generalizability of
studies that addressed insufﬁciently broad questions
or were conducted in other countries. This indicates
a lack of understanding by the participants and a
lack of economic expertise within their organiza-
tions that could help them adapt studies to their
own decision context. It also indicates an unwill-
ingness to fund local studies that might be consid-
ered more relevant.
Of more concern is the participants’ view that the
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clinical effectiveness data used in economic studies
is often of poor quality. This point needs further
examination to clarify the circumstances under
which the economic evaluations were carried out,
to see what is meant by clinical effectiveness, and
to see whether the problem was that the evaluation
missed good clinical data or that good clinical data
were not available at the time the study was done.
In the latter situation, which is not an infrequent
occurrence, the question arises as to what are
“good” clinical data. Any data on true clinical 
effectiveness are in short supply, especially for new 
technologies. Timeliness and relevance are key data
characteristics for decision making. Well-collected
data on tangentially related concepts such as efﬁ-
cacy are no substitute for the best available data on
the question to be answered.
So in addressing the problem of the failure of
NHS decision makers to make good use of 
economic information, what needs to change? We
should broaden our range of options. Changing the
way that NHS decisions are made, changing the
policy on funding local economic studies and exper-
tise, and changing the decision makers for people
with a better grasp of economics might be more
appropriate than distorting economic methods to
inform an unclear decision process.
Recent policy developments may resolve some 
of these issues as the NHS moves toward decen-
tralization of budget responsibility to primary care
trusts, while increasing the centralized production
of policy frameworks and clinical guidelines to
provide national templates for service delivery. 
Provided that these guidelines and frameworks 
take account of cost-effectiveness as well as clinical
factors, lack of economic expertise lower down in
the system may be less important. In any case the
role of health authorities will be much reduced in
the emerging structures, which may reduce the 
signiﬁcance of the results of studies such as that of
Hoffmann and colleagues.
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